Edit
Taris Biomedical
http://www.tarisbiomedical.com/Last activity: 21.12.2017
Active - Reference to ヤンセンファーマ
Location: United States, Massachusetts, Lexington
Total raised: $87.8M
Investors 1
| Date | Name | Website |
| - | RA Capital... | racap.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 21.12.2017 | Series B | $25M | - |
| 27.10.2015 | - | $32M | - |
| 03.04.2013 | - | $12.5M | - |
| 13.04.2011 | Series B | $18.3M | - |
Mentions in press and media 12
| Date | Title | Description |
| 21.12.2017 | TARIS Biomedical Raises $25M Series B | LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical LLC, a company developing targeted new therapies for millions of patients suffering from difficult-to-treat bladder diseases, announced today that it has raised $25M in a Series B financin... |
| 27.10.2015 | TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors | TARIS® emerges, after the sale of its lead asset to Allergan, as a new company focused on developing a broad portfolio of urology products Initial focus on bladder cancer and overactive bladder, using TARIS’ novel drug-device combination ap... |
| 27.10.2015 | Daily funding roundup - October 27, 2015 | Taris Biomedical raised $32M; SimilarWeb scored $25M; Spigit secured $13M Real-time consumer engagement app OnePulse has closed a $1.07 million seed investment round, led by AngelLab, D5 Capital and the London Co-Investment Fund along with ... |
| 27.10.2015 | Taris Biomedical Raises $32M in Venture Capital Funding | Taris Biomedical LLC, a Lexington, MA-based company using proprietary delivery technology and expertise in bladder biology to develop novel treatments for urologic diseases, raised $32m in funding. The round was led by Flagship Ventures wit... |
| 27.10.2015 | After a big-money Allergan deal, Taris returns with a $32M round and a new pipeline | Massachusetts' Taris Biomedical is getting back into R&D after flipping its lead asset to Allergan ($AGN) in a $587.5 million deal, raising $32 million to advance new treatments for bladder disease. The funds, courtesy of Flagship Ventu... |
| 03.04.2013 | Taris Biomedical Raises $12.5M in Financing | Taris Biomedical, a Lexington, Mass.-based specialty pharmaceutical company, raised $12.5m in financing. Backers included existing investors Flagship Ventures, Flybridge Capital Partners, Polaris Partners and Third Rock Ventures. The compan... |
| 02.04.2013 | TARIS Secures $12.5M | LEXINGTON, MA, Specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has raised an additional $12.5 million financing round through its e... |
| 13.04.2011 | TARIS Biomedical Raises $18.3M in Series B Financing | TARIS Biomedical, a Lexington, MA-based specialty pharmaceutical company developing innovative, targeted therapies using drug delivery to treat bladder diseases, has raised $18.3m in conjunction with its Series B financing. The round was le... |
| 13.04.2011 | Taris closes $18.3 million round | Taris Biomedical Inc. drummed up $18.3 million in its latest funding round. Lexington, Mass.-based company said the equity-based B round will support its lidocaine delivery technology developed at MIT to treat bladder conditions. Third Rock... |
| 13.04.2011 | Taris Biomedical raises $18M in funding round; targets bladder ailments | “This investment will allow us to advance our lead product candidate, Lidocaine Releasing Intravesical System (LiRIS), into later stage clinical development for the treatment of multiple bladder disorders, and to continue to build the rest ... |
Show more